Catalyst Intel Subscribe

Trial results

$TSHA — TSHA-102

Taysha Gene Therapies, Inc. (TSHA) TSHA-102: trial results in Rett syndrome, 2027.

Research by Catalyst Intel

The catalyst

"Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027"

— Taysha Gene Therapies, Inc., 8-K filed 2026-11-12 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id
TSHA-TSHA102-2026
Company
Taysha Gene Therapies, Inc.
Kind
Trial results
Indication
Rett syndrome
Window
2027-01-01 – 2027-06-30
Status
dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.